Benefical Effects of Sigma-1 Agonist Fluvoxamine for Tardive Dyskinesia and Tardive Akathisia in Patients with Schizophrenia: Report of Three Cases

Article

关键词: INDUCED MOVEMENT-DISORDERS;    NEUROPSYCHIATRIC DISORDERS;    RECEPTOR LIGANDS;    TOMOGRAPHY;    CHAPERONE;    DOPAMINE;    STRESS;    BRAIN;    DRUGS;   

DOI  :  10.4306/pi.2013.10.4.417

来源: SCIE

【 摘 要 】

Fluvoxamine is a selective serotonin reuptake inhibitor that is approved for psychiatric disorders such as major depressive episodes and obsessive-compulsive disorder. Beside inhibition of serotonin reuptake, fluvoxamine is also a potent agonist of endoplasmic reticulum (ER) protein sigma-1 receptors, which play a role in the pathophysiology of a number of psychiatric and neurodegenerative disorders. This report presents beneficial effects of sigma-1 agonist fluvoxamine on hyperkinetic movement disorders such as tardive dyskinesia and tardive akathisia. Fluvoxamine might be a novel treatmet approach in the treatment of hyperkinetic movement disorders.

【 授权许可】

Free